Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02
LOS...
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI 10...
The global microgrid market is witnessing rapid growth, primarily driven by the rising demand for energy resilience and reliability, especially in the face of grid...
The global microgrid market is witnessing rapid growth, primarily driven by the rising demand for energy resilience and reliability, especially in the face of grid...
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/...
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
August 8, 2025: Update
OTTAWA, ON, Aug. 8, 2025 /CNW/ -
This outbreak investigation is ongoing. The public health notice will be updated as the investigation...
NORTH BERGEN, N.J., Aug. 8, 2025 /PRNewswire/ -- DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to...